ASCO 2026 delivered a defining moment for precision oncology, and the 1Cell.Ai June 2026 Edition Newsletter captures why. From landmark trial data reshaping treatment sequencing to a deeper understanding of how tumours evolve resistance in real time, this month’s research signals that the field is moving faster than ever toward truly individualized cancer care. If you’re trying to keep pace with where the science is heading, this issue is a must-read.
At the heart of this issue is a compelling look at why KRAS mutation status alone doesn’t tell the whole story in metastatic pancreatic cancer. In collaboration with the Medical College of Wisconsin, 1Cell.Ai’s team uncovered striking findings using longitudinal ctDNA profiling: 65% of genomic alterations detected via cell-free DNA were completely missed in matched tissue biopsies, and 5 timepoints of dynamic clonal evolution were tracked in real time. For clinicians managing KRAS-targeted therapy decisions, this research offers a sobering and actionable reminder that monitoring clonal evolution may be just as critical as the initial mutation call.
Beyond the pancreatic cancer deep-dive, this issue also unpacks how OncoIndx® is evolving into a comprehensive multimodal profiling platform — integrating genomics, transcriptomics, and protein biomarkers into a single, more complete picture of each patient’s tumour biology. Add to that a roundup of the month’s top oncology headlines (from a KRAS-targeted therapy nearly doubling survival in metastatic pancreatic cancer, to AI models predicting drug response with multi-omic precision), and this issue gives you a fast, high-signal way to stay current with the trends that will shape your treatment decisions in the months ahead.